Type2 diabetes
Conditions
Interventions
The group to lose dose 50% insulin when add the Dulaglutide.
The group does not change the insulin dose when add the Dulaglutide.
Sponsors
Japan Red Cross Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The past three months , patients with type 2 diabetes are doing a basal insulin therapy with a fixed dose. Patient HbA1c value of consent acquisition time of 6.5 to 10%. Patient fasting serum CPR is greater than or equal to 0.5 ng / mL of consent acquisition point. Patient age at the time of obtaining informed consent is 20 years of age or older. Patients capable of obtaining the consent of the research participation by free will in writing from the person .
Exclusion criteria
Exclusion criteria: Type1 diabetes patients. Patients receiving insulin other than basal insulin. Patients who have used the GLP-1 receptor agonist in the past year. Patients who have a history of pancreatitis. During pregnancy , women who want to breast-feeding or during pregnancy . Patients attending physician has determined that there is a clinical problem in order to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of hypoglycemia | — |
Secondary
| Measure | Time frame |
|---|---|
| The amount of change from baseline in HbA1c. The amount of change from baseline in bodyweight. The amount of change from the insulin dose of baseline. Frequency of adverse events. | — |
Countries
Japan
Contacts
Public ContactTakashi Omura
Japan Red Cross Medical Center Department of Diabetes and Endocrinology
Outcome results
None listed